SLC5A2 and diabetes mellitus: While we found that diabetes was a univariate predictor of 30-day readmission only, there is now substantial evidence for use of SGLT2 inhibitors to reduce HF hospitalisations and all-cause death in HFrEF patients, with or without diabetes [30].